The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018
AIDS Patient Care STDS. 2021 Oct;35(10):392-400. doi: 10.1089/apc.2021.0087.
Gina M Simoncini1, Qingjiang Hou2, Kimberly Carlson2, Kate Buchacz3, Ellen Tedaldi1, Frank Palella , Jr4, Marcus Durham3, Jun Li3, HIV Outpatient Study (HOPS) Investigators
Author information
Collaborators
HIV Outpatient Study (HOPS) Investigators:
Kate Buchacz, Marcus D Durham, Jun Li, Cheryl Akridge, Stacey Purinton, Selom Agbobil-Nuwoaty, Kalliope Chagaris, Kimberly Carlson, Qingjiang Hou, Carl Armon, Linda Battalora, Frank J Palella, Saira Jahangir, Conor Daniel Flaherty, Kenneth S Greenberg, Barbara Widick, Rosa Franklin, Douglas J Ward, Linda Kirkman, Jack Fuhrer, Linda Ording-Bauer, Rita Kelly, Jane Esteves, Ellen M Tedaldi, Ramona A Christian, Faye Ruley, Dania Beadle, Richard M Novak, Andrea Wendrow, Stockton Mayer, Mia Scott, Billie Thomas, Cynthia Mayer, Victoria Franco, Karen Maroney
Affiliations
1Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA.
2Cerner Corporation, Kansas City, Missouri, USA.
3Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
4Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Abstract
Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection carries substantial risk for all-cause mortality and liver-related morbidity and mortality, yet many persons coinfected with HIV/HCV remain untreated for HCV. We explored demographic, clinical, and sociodemographic factors among participants in routine HIV care associated with prescription of direct-acting antivirals (DAAs). The HIV Outpatient Study (HOPS) is an ongoing longitudinal cohort study of persons with HIV in care at participating clinics since 1993. There are currently eight study sites in six US cities. We analyzed medical records data of HOPS participants diagnosed with HCV since June 2010. Sustained virological response (SVR) was documented with first undetectable HCV viral load (VL). We assessed factors associated with being prescribed DAAs by multi-variable logistic regression and described the cumulative rate of SVR. Among 306 eligible participants, 131 (43%) were prescribed DAA therapy. Factors associated with greater odds of being prescribed DAA were older age, private health insurance, higher CD4 cell count, being a person who injects drugs, and receiving care at publicly funded sites (p < 0.05). Of 127 (97%) participants with at least 1 follow-up HCV VL, 110 (87%) achieved SVR at 12 weeks. Of the total 131 participants, 123 (94%) eventually achieved SVR. Less than half of HIV/HCV coinfected patients in HOPS have been prescribed DAAs. Interventions are needed to address deficits in DAA prescription, including among patients with public or no health insurance, younger age, and lower CD4 cell count.